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Abstract
Objectives PH46A (1) demonstrates significant anti-inflammatory activity in
phenotypic models but its mechanism and site of action have been elusive. Cur-
rent study focused on the bioactivity of PH46 (2) and related novel indane
dimers (6-10) to investigate the impact of changes in substitution and stereo-
chemistry at the C-1 and C-2 positions of the PH46 (2) scaffold.
Methods Cytotoxicity profiles of compounds were established using THP-1
macrophages and SW480 cells. Effects of the compounds were then evaluated at
10 µM using 5-lipoxygenase (LOX) and 15-LOX enzymes, and 5-LOX binding
was evaluated in silico against NDGA, nitric oxide (NO) released from LPS-in-
duced SW480 cells and cytokines in THP-1 macrophages (IL-6, IL-1b, TNF-a
and IFN-c) and in SW480 cells (IL-8).
Key findings PH46 (2) and 7 cause reduction in NO, inhibition of 5-LOX with
high binding energy and no cytotoxicity effects in THP-1 macrophages and
SW480 cell lines (up to 50 µM). The cytokine profiling of the series demonstrated
inhibition of IL-6 and TNF-a in THP-1 macrophages together with IL-8 in
SW480 cells.
Conclusions The observed profile of cytokine modulation (IL-6/ TNF-a, IL-8)
and inhibition of release of NO and 5-LOX may contribute to the in vivo effects
demonstrated by indane dimers and PH46A (1) in murine models of colitis.
Introduction
The indane (2,3-dihydro-1H-indene) ring system consists
of a combination of aromatic benzene and aliphatic
cyclopentane ring as shown in Figure 1. This gives a broad
diversity of chemical entities with indane as the core struc-
ture. The ring system can accommodate substituents on its
aliphatic and on its aromatic moiety which can modulate
the biological properties of the molecule.[1] This versatility
has contributed to indane being identified as a privileged
structure.[2] The indane ‘scaffold’ also commonly occurs
naturally or in medicinal chemistry as indanones, indan-
diones and indanols.[3]
The current study is based on molecules that have been
developed in our group over the last 20 years. These studies
centred on the synthesis and evaluation of the pharmacologi-
cal activity of nature identical and synthetically modified
indanes, indanones and dimeric indane. One of these mole-
cules, PH46A (1) or 6-(Methylamino)hexane-1,2,3,4,5-pen-
tanol 4-(((1S,2S)-1-hydroxy-2,3-dihydro-1H,10H-[2,2-
biinden]-2-yl)methyl)benzoate) has advanced to clinical trial
(ISRCTN90725219) (singular). PH46A (1) is a first in class
with a novel scaffold.[4] In early studies, simple monomeric
indanes, with a structure based on the natural pterosin scaf-
fold, were designed and shown to demonstrate smooth mus-
cle relaxant and mast cell stabilisation effects.[5–8] Subsequent
work led to the development of dimeric indane molecules
which demonstrated mast cell stabilisation activities, with
twice the order of magnitude than the monomeric indane
series.[9,10] At that point we considered the potential of the
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series for their clinical use as new chemical entities in the pre-
vention of asthma based on their combined mast cell stabili-
sation and muscle relaxant properties.
As studies progressed, we revealed that the series of lead
molecules also had significant anti-inflammatory and
immune-modulating activity. On evaluation in vivo, the
lead compounds showed significant activity in several mod-
els of murine colitis, for example, PH46 (2) reduced colon
cytokine levels of TNFa, IL-6 and IL1b in DSS colitis
mice.[4] These molecules also prevented histological dam-
age to colons. From these results, a lead molecule PH46A
(1) demonstrated efficacy in two murine models of inflam-
matory bowel disease (IBD): an acute dextran sulphate
sodium (DSS) model of murine colitis and the more
chronic spontaneous model of IL-10/ colitis mice.[4] The
scaffold of PH46A (1) incorporates the indane skeleton and
is the N-glucamine salt of a single enantiomer PH46 (2) of
this novel drug with 1S, 2S stereochemistry at the C-1 and
C-2 positions. The success of PH46A (1) in ameliorating
the effects of in vivo activity in the DSS and IL-10/ mur-
ine model of colitis has led to its potential as a therapeutic
agent in IBD. It is interesting to note that of the four possi-
ble enantiomers forming the isomeric dimeric indane
scaffold that with the 1S, 2S stereochemistry at C-1 and C-2
(as shown in Figure 1) gave optimal results in the in vivo
colitis studies.
Despite the impressive in vivo results observed for
PH46A (1), the absence of understanding the molecular
target has prompted further investigation into the activity
of PH46A (1) and PH46 (2), and some analogues in order
to build understanding of what may be a novel, complex
mechanism of action or biological fingerprint. Within the
series there is currently no clear understanding of the effect
of substitution at the C-1 and C-2 positions on the phar-
macological activity of analogous compounds, although
our earlier work has identified what appears to be an opti-
mal stereochemical configuration for the enantiomers of
PH46 (2).
In the current study, for the first time, we have charac-
terised the bioactivity of these novel indane dimers in
in vitro, in vivo and in silico models. This allows us to
understand the relationship of stereochemistry and substi-
tution at the C-1 and C-2 positions on indanol ring B on
biological activity (Figure 1). The results of the bioactivities
have enabled us to progress to a deeper understanding in
the pharmacological fingerprint of the indane dimers in the
Figure 1 Indane, isomeric indane dimer scaffold; PH46A (1) and PH46 (2).
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development of potential therapeutic agents in IBD and
other related inflammatory diseases.
Materials and Methods
Synthesis of indane dimers
PH46A (1) and PH46 (2) were synthesised according to the
experimental method previously reported.[4] The key com-
pounds of interest 6 and 7 were synthesised from 3, with
intermediate compounds 4 and 5[11,12] (Scheme S1). Com-
pound 8 was supplied by Trino Therapeutics Ltd and was
used as intermediate compound to synthesise compounds 9
and 10 (Scheme S2).[9,10,13]
Measurement of cytotoxicity of test
molecules on THP-1 and SW480 cells using
acid phosphatase assay
THP-1 monocytes (ATCC TIB-202; LGC Standards, Middle-
sex, UK) and SW480 cells were seeded in 96-well plates at
concentration 4 9 104 per well in 100 µl. For THP-1 mono-
cytes, the cells were differentiated with 200 nM of PMA
(Sigma-Adrich, Darmstadt, Germany) for 48 h. The PMA-
differentiated macrophages were cultured and left at resting
period for 3 days (PMAr stage).[14] For SW480, the cells
were seeded in 96-well plates 24 h prior to drug incubation
at 10 µM. After 24 h, the media were removed and each well
was washed with 100 µl of PBS and the step was repeated
twice. After washing, 100 µl of freshly prepared phosphatase
substrate (10 mM p-nitrophenyl phosphate in 0.1 M
sodium acetate, 0.1% Triton X-100, pH 5.5) was added into
each well. The plates were incubated in the dark at 37°C
and 5% CO2 for 1 h. The reaction was stopped by adding
20 µl of Na OH. Readings of the wells were recorded at
405 nm.[15]
Measurement of 5-LOX inhibition by test
molecules using UV-Vis spectrophotometric
assay
Briefly, 100 µl of 2.75-unit human recombinant 5-LOX (fi-
nal concentration is 0.5 unit/ml) (Cayman Chemicals, Ann
Arbor, MI, USA) was pre-incubated with 50 µl of com-
pounds/standard inhibitor/buffer, 100 µl of 2.2 mM CaCl2
(final concentration is 0.4 mM), 100 µl of 132 µg/ml L-a-
phosphatidylcholine type II-S (final concentration is 24 µg/
ml) and 100 µl of 1.1 mM ATP (final concentration is
0.2 mM) at RT for 5 min in the dark. The reactions were
started by adding 100 µl of 275 µM arachidonic acid (final
concentration is 50 µM) to the mixture in quartz microcu-
vettes. The mixture was gently mixed by pipetting three
times and the increase in absorbance at 234 nm was
measured using the Shimadzu UV-1602 spectrophotome-
ter. The compounds were screened using one concentration
point to determine the percentage inhibition by following
the formation of the conjugated diene product 5-HpETE at
234 nm (e = 25 000 M1 cm1).[16]
Measurement of 15-LOX inhibition by test
molecules using FOX enzymatic assay
In the sample wells, 50 µl of rabbit reticulocyte 15-LOX-1
(2 µl from purified stock at 5000 units/ml; Enzo Life
Sciences, Farmingdale, NY, USA) was pre-incubated with
50 µl of compounds/standard inhibitors (final concentration
is 30 µM) at 25°C for 5 min. The control well consisted of
50 µl of rabbit reticulocyte 15-LOX-1 and 50 µl of buffer in
0.2% DMSO. The reaction was initiated by adding 50 µl of
arachidonic acid (final concentration of 50 µM) into both
the sample and control wells. The reaction mixture was incu-
bated at 25°C for 15 min in the dark. The reaction was ter-
minated by adding 100 µl of FOX reagent after reaction
period of 15 min. The FOX reagent contained 30 mM sul-
phuric acid, 100 µM xylenol orange and 100 µM ferrous (II)
sulphate in MeOH : water (9 : 1). The absorbance readings
were measured at 584 nm after 30 min of colour develop-
ment at RT.[17]
Measurement of nitric oxide inhibition by
test molecules using GREISS assay
SW480 cells were stimulated with 1 µg/ml of Salmonella
enterica serotype typhimurium LPS and IFN-c[18] (Sigma-
Aldrich). The treatment of cells with LPS was carried out
for 48 h, at 37°C under 5% CO2. After treatment, the cul-
ture supernatant was collected and immediately tested for
nitrite quantitation using GREISS reagent. Equal volume of
fresh culture supernatant and sulphanilamide solution was
loaded into each well of 96-well plates. The mixture was
incubated for 10 min, in the dark at RT. Next, same vol-
ume of N-1-napthylethylenediamine dihydrochloride
(NED) was added into each well and incubated for 20 min.
A purple/magenta colour was formed in the wells and the
absorbance was recorded at 540 nm. A standard curve
(0–100 µM) of NO2
 was developed using known standards
as provided by the kit.
Cytokine profiling using THP-1 and SW480
cells
THP-1 macrophages
THP-1 monocytes were seeded in 24-well plates at density
of 2.5 9 105 cells per well in 500 µl. The differentiation
process and resting period of the THP-1 macrophages were
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carried out and adapted.[14] After 1 h of drug exposure, the
cells were stimulated with 1 µg/ml of Escherichia coli 0111:
B4 LPS (Sigma-Aldrich). At 24 h, the media were collected
from each well, transferred into 2.0-ml microcentrifuge
tubes and centrifuged at 17 950 g for 10 min at 4°C. Super-
natant collected was analysed using MSD V-PLEX Proin-
flammatory Panel 1 Human (4-Plex) Cat. No K15052D and
V-PLEX individual assay Cat. No. K151QUD kits (Meso
Scale Diagnostics, Rockville, MD, USA).
SW480 cells
SW480 cells were seeded into 96-well plates at density
49 104 cells/well and left to grow until 80% confluency. The
cells were stimulated with 1 µg/ml of E. coli 0111: B4 LPS
after 1 h of drug treatment. Supernatant was collected from
each well at 24 h. The supernatant was transferred into 2.0-
ml microcentrifuge tubes and centrifuged at 13 000 rpm for
10 min at 4°C. Supernatant collected was analysed using
MSD U-PLEX Biomarker Group 1 Human (10-Plex) Cat.
No. K15067L-2 (Meso Scale Diagnostics) plates.
Molecular docking of test molecules using
5-LOX
As a first step in molecular modelling compounds 2, 6, 7, 8,
9 and 10 and the reference standard nordihydroguaiaretic
acid (NDGA) were prepared using LigPrep[19] tool of the
Schr€odinger[19] software to generate the 3D structures. Dur-
ing the process, input ionisation states were retained and
chiralities were determined from 3D structures. Final struc-
tures were minimised using optimised potential liquid simu-
lations (OPLS3e) force field.[20] Structure of the target
protein also needs to be prepared before going further into
in silico calculations. Accordingly, crystal structure of human
5-LOX (PDB ID: 3V99, 2.252 A) in complexed with arachi-
donic acid was retrieved from RSCB protein data bank and
subjected to Protein Preparation Wizard module of
Schr€odinger’s.[21,22] Bond orders were assigned, missing
hydrogens were added, chain B, all water molecules and het-
eroatoms except arachidonic acid were removed. In the next
step, the structure was optimised and further minimised
using OPLS3e force field to avoid steric clashes. Arachidonic
acid was taken as a reference to define the binding site of
5-LOX. A grid representing the binding site was generated
using default settings. Glide XP (extra precision)[23] module
was used to dock the compounds into the binding pocket.
Statistical evaluation
Statistical comparisons (GraphPad Prism 5.01; GraphPad
Software, San Diego, CA, USA) were made using one-way
ANOVA with P < 0.05 considered as statistically
significant. Dunnett’s Multiple Comparison Test was cho-
sen to compare between the control group and samples
groups. Subsequently, Bonferroni’s Multiple Comparison
Test was used to compare the samples groups in the cytoki-
nes ‘profiling to evaluate the SARs’. The results were
expressed as the mean  standard error mean (n = 3
experiments performed on different days), unless otherwise
stated. Asterisks indicate the value is significant (*P < 0.05;
**P < 0.01; ***P < 0.001).
Results
Cytotoxicity effects on THP-1 and SW480
cells
In the current study, 30 µM was selected as the tested con-
centration with addition of one higher and one lower con-
centrations: 50 and 10 µM, respectively. From Figure 2a
and 2b, it was observed that none of the compounds exhibit
any significant cytotoxic activities at the highest concentra-
tion of 50 µM in either THP-1 macrophages or SW480.
This study allowed us to establish a dose range for incuba-
tion of test compounds in a non-toxic dose range.
Measurement of 5-LOX and 15-LOX
inhibition
Of the compounds screened at 10 µM, only PH46 (2) and
methylene analogue 7 inhibited 5-LOX significantly at
45.30  5.28% and 39.71  4.95%, respectively, P < 0.05.
Results were comparable to the degree of inhibition of
zileuton at 45.22  5.36%, P < 0.05. The % inhibition of
control NDGA was observed at 51.92  1.01%, P < 0.05,
as shown in Figure 3a. The indane dimers did not give any
significant inhibition of 15-LOX (Figure 3b) and control
NDGA at 10 µM inhibited 15-LOX activity at
72.43  3.25%. The Z0-factor in this 96-well microplate
ferrous oxidation-xylenol orange (FOX) assay was deter-
mined as 0.891 which demonstrated the suitability for mid-
throughput to high-throughput screening.[24] The IC50
value for NDGA was determined at 4.61  0.93 µM, simi-
lar to the literature values.[25].
Docking analysis using 5-LOX
As shown from Table 1, the active compounds against 5-
LOX 2 and 7, together with the reference compound
NDGA, had the highest score. Besides a number of
hydrophobic interactions, NDGA makes strong hydrogen
bonds with Val671, HIS367, THR 364 and GLN363 in the
binding pocket. In addition, a favourable T-shaped p- p
interaction with HIS367 is also observed. Docking analysis
of the active compound 2 indicates that the hydroxy group
© 2020 Royal Pharmaceutical Society, Journal of Pharmacy and Pharmacology, ** (2020), pp. **–**4
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at C-1 position participates a hydrogen bonding with
HIE550 of 5-LOX. No other hydrogen bond is observed
but the carboxy group orients itself towards polar LYS409
suggesting a possible favourable interaction.
Hydrophobic interactions of indene moiety with
PHE610, LEU607, AL604 and THY558 also contribute to
the binding of 2 and reduce the energy of protein–ligand
complex which in turn enhances activity. In compound 6
where hydroxy group at C-1 position of 2 is replaced by
carbonyl group, a new hydrogen bond is observed between
carboxy group and VAL671 which may compensate the
absence of favourable interaction of -OH group. However,
compound 6 was observed to adopt a different orientation
in the 5-LOX binding pocket. Most noticeable, an unfa-
vourable face-to-face p-p interaction between indene ring
and PHE177 is observed (the angle between the ring planes
is 20.5°). Hence, the favourable hydrophobic interaction of
indene moiety is now replaced with unfavourable p-p
stacking interaction (Figure 4).
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Figure 2 Preliminary cytotoxicity screening at 10, 30 and 50 lM determined by acid phosphatase assay after incubation for 24 h: (a) THP-1
macrophages and (b) SW480 cells. Results were expressed as mean  standard error mean (SEM; n = 4). No significant (*P < 0.05) values were
observed.
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Figure 3 LOXs inhibitory activities of indane dimers and standard inhibitors using; (a) 5-LOX (b) 15-LOX. Results were expressed as mean  stan-
dard error mean (SEM; n = 3). Asterisks indicate the value is significant (*P < 0.05; **P < 0.01). LOX, lipoxygenase.
Table 1 Docking scores of nordihydroguaiaretic acid (NDGA) and
compounds 2, 6-10
Compound Docking Score (kcal/mol)
NDGA 9.36
7 6.30
2 6.07
8 5.63
6 5.60
10 5.21
9 4.40
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Measurement of nitric oxide inhibition
Preliminary screening of the indane dimers (Figure 5)
showed comparable inhibition to the positive control,
hydrocortisone at 10 µM (43.55  12.27%) but did not
show statistical significance due to a slight increase in SEM
at n = 3. A second positive control, the natural product
and nitric oxide (NO) inhibitor, a-mangostin[26] gave an
inhibition of 61.63  7.50% with P < 0.01. Of the ana-
logues examined, PH46 (2) exhibited the highest inhibition
with 56.50  3.09%. Para-carboxybenzyl derivatives 6, 7
and the para-unsubstituted benzyl 9 also inhibited NO pro-
duction. IC50 values were determined for analogues which
inhibited at greater than 50% at the selected 10 µM concen-
tration. The IC50 value of a-mangostin was determined at
8.87  1.18 µM and this value is close to the reported val-
ues of IC50: 12.2 µM.
[26] The IC50 value of hydrocortisone
was 48.66 µM consistent with literature values.[27] PH46 (2)
displayed the lowest IC50 value of 19.70  7.88 µM of all
the analogues, followed by compound 9 (IC50:
20.49  2.89 µM).
Cytokine profiling using THP-1 and SW480
cells
IL-6 plays a central role in the maintenance of chronic
intestinal inflammation in IBD.[28] The level of IL-6 in
THP-1 macrophages stimulated with LPS without drug
treatment was 1.666  0.256 pg/µg ml in CTRL 1 as
shown in Figure 6a. CTRL 2 represented the level of IL-6 in
Figure 4 Calculated 3D binding interactions of nordihydroguaiaretic acid (NDGA) (top left), 2 (bottom left) and 6 (right) with 5-LOX. Amino acid
residues are coloured by properties (Hydrogen bonds: yellow dashed lines; p-p interactions: cyan dashed lines; hydrophobic: green; polar: cyan;
positively charged: purple). For the sake of clarity, only discussed crucial amino acids are shown. LOX, lipoxygenase.
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cells without LPS stimulation, at 0.0015  0.016 pg/µg ml.
The Cyclosporine A control significantly reduced the pro-
duction of IL-6 from the value of 1.666  0.256 pg/µg ml
to 0.161  0.053 pg/µg ml, with P < 0.001. Infliximab did
not inhibit IL-6 significantly from the value of
1.666  0.256 pg/µg ml to 0.924  0.180 pg/µg ml. Inflix-
imab was used as the positive control as it inhibits the pro-
duction of TNF-a and is used as anti-TNF-a therapy for
IBD treatment clinically.[29,30] PH46 (2) and compound 8,
its unsubstituted benzyl analogue, displayed potent IL-6
inhibition with levels of inhibition of 92.07%
(0.132  0.038 pg/µg ml) and 95.49% (0.075  0.019 pg/
µg ml), respectively, over CTRL 1.
Cytokine IL-1b triggers intestinal inflammation by aug-
menting the recruitment of granulocytes and the activation
of intestinal epithelial cells (IECs).[31] In Figure 6b, the
level of IL-1b in CTRL 1 was 0.329  0.042 pg/µg ml vs
level of IL-1b in CTRL 2 at 0.045  0.015 pg/µg ml.
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Ciclosporin A stimulated production of IL-1b signifi-
cantly with P < 0.001, at 1.784  0.052 pg/µg ml. Inflix-
imab did not have significant inhibitory effect on IL-1b,
with production level at 0.329  0.059 pg/µg ml. No sig-
nificant inhibition was observed by analogues in the
study. TNF-a has been shown to induce various inflam-
matory mediators in the inflamed mucosa in IBD.[32] In
the cytokine profiling for TNF-a, the level of TNF-a for
CTRL 1 was measured at 22.305  2.753 pg/µg ml,
whereas CTRL 2 (without LPS stimulation) measured at
0.060  0.019 pg/µg ml as shown in Figure 6c. Inflix-
imab at 10 µM effectively inhibited the production of
TNF-a with % inhibition of 99.98%, measuring at
0.002  0 pg/µg ml, p < 0.001. Cyclosporine A slightly
inhibited the release of TNF-a at 17.57%
(17.460  2.249 pg/µg ml) at 10 µM, but the value was
not statistically significant. The profiling of TNF-a was
like IL-6 where PH46 (2) and 8 inhibited TNF-a at
45.18% (11.613  0.162 pg/µg ml) and 32.99%
(14.193  1.685 pg/µg ml) respectively. These com-
pounds both have a hydroxyl group with the S-configura-
tion at C-1 position which may play a role in assisting
TNF-a inhibitory activity.
Studies have shown that the production of IFN-c is
increased in lamina propria and T cells in patients with
IBD.[33] In this study, the release of IFN-c was low com-
pared with the other three analytes under the same experi-
mental conditions. The level of IFN-c in LPS-stimulated
THP-1 macrophages was 0.024  0.007 pg/µg ml and
0.001  0.000 pg/µg ml in THP-1 macrophages without
LPS stimulated. Cyclosporine A inhibited IFN-c with %
inhibition of 68.05% (0.008  0.001 pg/µg ml, P < 0.01)
as shown in Figure 6d. It was observed that the indane
dimers inhibited production of IFN-c significantly, with
activity ranging from 70.0 to 85.0% in all the molecules
except 6 and the activities are comparable with cyclospor-
ine A. Some groups exhibited greater variability due to the
low detection of IFN-c.
IL-8 is a potent angiogenic factor in colon wound heal-
ing, colitis and cancer. In patients with IBD, IL-8 is overex-
pressed and generally localised to areas of active
inflammation and tissue damage.[34,35] Overall the inhibi-
tion over CTRL 1 values range from 12.70 to 25.0% for the
mentioned molecules as shown in Figure 7. CTRL 1 (with
LPS stimulation) was measured at 3.324  0.076 pg/µg ml
vs CTRL 2 (without LPS stimulation) at 0 pg/µg ml,
P < 0.001. Cyclosporine A inhibited IL-8 with P < 0.05,
measuring at 2.689  0.293 pg/µg ml. The inhibitory
effects observed with PH46 (2) and compound 8 on IL-6
and TNF-a release from THP-1 macrophages were also
observed on the release of IL-8 from SW480 cells with
P < 0.05, 23.92% (2.529  0.058 pg/µg ml) and 31.17%
(2.288  0.059 pg/µg ml) respectively. In addition,
compound 7 inhibited IL-8 measuring at 19.49%
(2.676  0.142 pg/µg ml), P < 0.05. The effect of this
molecule on IL-6 release from THP-1 macrophages was less
potent but statistically significant.
Discussion
The effects of PH46 (2) and the indane dimers (6-10) on
5-LOX, NO and on the production of inflammatory media-
tors from THP-1 macrophages and SW480 cells were
investigated. PH46 (2) was selected for these studies, to
facilitate comparison with other close analogues for which
there was no salt available or for which suitable salts could
not be prepared. The selection of PH46 (2) over PH46A (1)
is justified given that in vitro and clinical data has shown
that PH46A (1) dissociates in solution to PH46 (2) and the
N-glucamine salt.[4]
To establish the concentration range of the indane
dimers that could be used in in vitro cell studies com-
pounds, cell viability screening of the novel compounds
was evaluated at 10, 30 and 50 µM against the THP-1
human monocytic cell line, which is a model for the evalua-
tion of immune-modulating effects of compounds[36] and
the SW480 cells.[37] The optimised concentration in high-
throughput drug screening is 30 µM for cell-based assays to
minimise the effects of false-positive results.[38] None of the
compounds exhibits any significant cytotoxic activities at
the highest concentration of 50 µM in either THP-1 macro-
phages or SW480.
Earlier studies have shown that the in vivo anti-inflam-
matory effects of the indane dimers (1, 2 and 8) are inde-
pendent of cyclooxygenase (COX) (Frankish & Sheridan
unpublished results). The zileuton (12), is a bioisostere of
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Figure 7 Effects of indane dimers at 10 lM on IL-8 from LPS-
induced SW480 cells. Results were expressed as mean  standard
error mean (SEM; n = 3). Asterisks indicate the value is significant
(*P < 0.05; **P < 0.01; ***P < 0.001).
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indane, and is also an orally active inhibitor of the 5-LOX
enzyme and was used in this study as a positive control.
The ability of bioisosteres to elicit similar biological activ-
ity has been attributed to common physicochemical prop-
erties.[39] The 5-LOX plays a unique role in the
production of leukotrienes which makes it a potential
therapeutic target for inflammatory conditions like
asthma, rheumatoid arthritis, psoriasis and IBD.[40] Due
to the involvement of 5-LOX in IBD and the profound
activity observed for PH 46A (1) and PH 46 (2) and its
analogues in in vivo colitis models,[4] the activity of PH46
(2), the indane dimers (6-10) and positive controls 12
and phenidone was evaluated on 5-LOX and 15-LOX
enzymes, to see if LOX activity is part of the pharmaco-
logical fingerprint of the series. Furthermore, molecular
docking calculations were performed to further support
biological activity results towards 5-LOX. Docking calcu-
lations revealed that binding site of 5-LOX is composed
of both hydrophilic and hydrophobic amino acid residues.
Active inflammation of the colon lining during IBD is
associated with increased production of cytokines released
by the colonic cells, macrophages and neutrophils. These
cytokines such as IFN-c and TNF-a induce the release of
inducible NO synthase (iNOS) via nuclear factor-jB (NF-
jB) pathway which results in increased production of
NO.[41] NO overproduction via iNOS upregulation by
intestinal epithelium has been consistently associated with
IBD.[42] The effects of compounds, PH46 (2) and the indane
dimers (6-10) on NO inhibition were evaluated in this
study, to elucidate if such activity may be a contributing fac-
tor to the observed beneficial in vivo effects of the novel scaf-
fold in murine colitis models. Although this study does not
probe the mechanism of NO inhibition, and will need to be
expanded, it suggests that NO inhibition may be a signifi-
cant activity for the lead molecule PH46 (2) and may be a
contributing factor to the effects observed in in vivomodels.
To understand the impact of the indane dimer scaffold
on cytokine production, we evaluated the effects of PH46
(2) and the related dimers (6-10) on the four primary
cytokines released by the THP-1 macrophage cell line;
TNF-a, IL-1b, IL-6 and IFN-c, and on IL-8 released from
SW480 cells. The indanes screened initially at 10 µM with
drug incubation for 24 h. The total protein for the samples
was determined. Measurement of each cytokine was repre-
sented by the concentration of each cytokine (pg/ml),
expressed in relative to total protein quantified (µg) using
BCA assay to give the final unit in pg/µg ml. Infliximab
and cyclosporine A were used as positive controls similar
to the previous study[43] and they are known as standard
medications used to treat IBD. The results obtained for the
quantification of IL-8 in SW480 showed that there was a
statistically significant inhibition of IL-8 release by some of
the indane dimers with a methylene group at C-2 position.
The current study focused on probing activities that
contribute to the pharmacological fingerprint of PH46 (2)
and related molecules that might explain activity observed
in in vivo phenotypic models. The study of the analogous
series also aimed at understanding how substitution and
stereochemistry at the C-1 and C-2 position of the B ring
in the indane dimer scaffold might contribute to the
observed biological activity. Specifically, we investigated
the impact of subtle modification at C-1 and C-2 posi-
tions of the B ring in the dimers. The indane dimers,
PH46 (2) and its C-1 methylene derivative 7 inhibited 5-
LOX significantly (p < 0.05). These compounds have the
S-para-carboxybenzyl substituent at C-2. The molecules
differ in substitution at C-1, where 7 has no OH group,
but both molecules retain sp3 hybridisation at this posi-
tion, which may impact on binding with the isozymes.
The observed inhibition of 5-LOX was further supported
during molecular docking analysis which has shown high-
est docking scores for indane dimers PH46 (2) and 7.
None of the test compounds showed a binding affinity
with 15-LOX (Table 2). The cytokine profiling using THP-
1 macrophages (IL-6, IL-1b, TNF-a and IFN-c) and
SW480 cells (IL-8) has identified a few key compounds
with optimal substituents at the C-1 and C-2 positions. The
two most active indanes 2 and 8 with the hydroxyl group at
Table 2 Effects on novel indane dimers and standard inhibitors with significant values (p < 0.05) on the target IBD-related factors
LOXs THP-1 macrophages SW480 cells
5-LOX 15-LOX Cytotoxicity IL-6 IL-1b TNF-a IFN-c Cytotoxicity IL-8 NO
2 Y Y Y Y Y Y
6 Y
7 Y Y Y Y Y
8 Y Y Y Y
9 Y Y Y
10 Y Y
Nordihydroguaiaretic acid (NDGA) Y Y
Cyclosporine A Y P Y Y
Infliximab Y
Y-inhibits; P-potentiates. LOX, lipoxygenase.
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C-1 had been shown to have potential for the treatment of
IBD in previous studies.[4,9] This study shows that they
inhibit the key mediators IL-6 and TNF-a in THP-1 macro-
phages and IL-8 in SW480 cells.
The activity of 2, 6 and 7 with the para-carboxybenzyl
substituent at the C-2 position, and the activity of 9, with
just the benzyl group at C-2 suggest that the para-carboxy
group does not contribute significantly to NO inhibition.
The substituent at C-1 conferring the greatest activity for
indane dimers is an S-hydroxyl group as observed in 2, the
most active compound. Overall, the effects of PH46 (2) and
the novel analogues (6-10) on the key mediators with sig-
nificant values at p < 0.05 are summarised in Table 2.
Conclusion
The biological fingerprint of PH46 (2) and the related novel
indane dimers (6-10) has been evaluated in in vitro, in vivo
and in silico models and these studies have contributed to
our understanding of this novel class of molecule. The cyto-
kine profiling of the series demonstrated inhibition of IL-6
and TNF-a in THP-1 macrophages and IL-8 in SW480
cells. PH46 (2) and 7 cause a statistically significant reduc-
tion in NO production and reduction in 5-LOX activity in
the arachidonic acid pathway. These activities should be
considered to form part of the indane dimer biological fin-
gerprint and may contribute to the in vivo effects demon-
strated by PH46 (2) in murine models of colitis. PH46 (2)
reduced DAI in the acute 5% DSS and IL-10 -/- murine
model of colitis and significantly reduced MPO activity, a
measure of inflammatory cell infiltration and inflammatory
colon cytokines (IL-6, IL-1b and TNF-a).[4] The observa-
tion of inhibition of NO and 5-LOX by PH46 (2) and other
related indane molecules warrants further study and may
help to elucidate a clearer understanding of the relationship
between the reduction in inflammation in the in vivo mod-
els and the decreased level of cytokines observed. Further
investigations will lead to a deeper understanding of the
pharmacological fingerprint to identify potential develop-
ment of anti-inflammatory therapeutic agents.
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